Episode 216: Update on Broluciziumab Safety Including HAWK/HARRIER Phase 3 Trial Data

Drs. Thomas Albini, Aleksandra Rachitskaya, and Charles Wykoff of the Vit-Buckle Society join for a group discussion of brolucizimab safety data including a discussion of idiopathic ocular inflammation and arterial occlusions from HAWK/HARRIER Phase 3 trials, post-market reports of adverse events, and approach to utilizing brolucizumab going forward.

Om Podcasten

An informal yet insightful commentary featuring interviews and perspectives from leaders in vitreoretinal surgery as well as the next generation of retinal specialists